Communiqués

23/06 Saniona: Our take on the SAN2668 R&D day AQ
11/06 Three shots on goal: Saniona prepares to enter the clinic AQ
04/06 Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies AQ
28/05 Saniona (Q1 Review): Setting up for the long run AQ
27/05 Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026 AQ
26/05 SANA : Interim Report Q1 2026 PU
26/05 Saniona publishes its interim report for the first quarter of 2026 AQ
20/05 Invitation to Saniona Q1 investor call on 26 May 2026 AQ
30/04 Saniona publishes its Annual Report for 2025 AQ
27/04 SANA : The board's statement pursuant to Chapter 19, Section 22 of the Swedish companies Act PU
24/04 SANA : Notice of annual shareholders' meeting 2026 PU
24/04 SANA : Proposal for resolution on LTI 2026 PU
24/04 SANA : Notice of Saniona AB annual shareholders' meeting PU
24/04 Notice of Saniona AB annual shareholders’ meeting AQ
12/03 Saniona enters clinical execution phase following transformational year AQ
12/03 Meet Saniona at several conferences during the spring AQ
03/03 Saniona (Q4 review): Moving forward nicely AQ
26/02 Saniona publishes its year-end report for 2025 AQ
20/02 Invitation to Saniona Q4 & year-end investor call on 26 February 2026 AQ
17/12 Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs AQ
01/12 Saniona comments on major advancements during third quarter AQ
28/11 Saniona (Q3 Review) - Gearing up for clinical development AQ
27/11 Saniona publishes its interim report for the third quarter of 2025 AQ
20/11 Invitation to Saniona Q3 investor call on 27 November 2025 AQ
06/11 Saniona AB’s Nomination Committee for the Annual General Meeting 2026 AQ
Aucun résultat pour cette recherche